BCG Therapy Should Be Postponed in Patients with Active UTI
Do not administer intravesical BCG therapy in the presence of an active urinary tract infection. 1 The presence of active infection is a clear contraindication to BCG instillation due to the risk of systemic absorption and potentially life-threatening BCG sepsis.
Clinical Algorithm for Managing UTI During BCG Therapy
Step 1: Distinguish Between Active UTI and Asymptomatic Bacteriuria
Active UTI (symptomatic):
- Postpone BCG instillation immediately 2
- Perform urine culture 2
- Start empirical antibiotic treatment with oral quinolone antibiotics 2
Asymptomatic bacteriuria (ABU):
- BCG can be safely administered 1, 3
- Evidence shows ABU does not increase side effects, BCG toxicity risk, or affect recurrence rates 1
- Routine screening for ABU before BCG is not recommended as it creates unnecessary cost and treatment delays 3
Step 2: Management of Persistent Symptoms After Initial Antibiotic Treatment
If symptoms persist beyond 48 hours despite antibiotics 2:
- Continue to postpone BCG instillation
- With positive culture: Adjust antibiotic treatment according to sensitivity 2
- With negative culture: Consider intravesical instillation therapy with quinolones and anti-inflammatory/analgesic drugs, once daily for 5 days (repeat if necessary) 2
Step 3: When to Resume BCG Therapy
- Resume BCG instillations only when symptoms have completely resolved 2
- Ensure adequate time has passed since antibiotic completion
- Critical timing note: Quinolones should not be administered within 6 hours prior to BCG instillation, as antibiotics can kill BCG bacteria and eliminate therapeutic efficacy 1
Key Distinctions and Clinical Pitfalls
The Asymptomatic Bacteriuria Exception
The most important nuance here is distinguishing between symptomatic UTI and asymptomatic bacteriuria. A 2017 systematic review found that asymptomatic bacteriuria in 61 of 243 patients receiving BCG did not increase side effects or toxicity risk and had no impact on recurrence rates 1. This is Level B evidence that should reassure clinicians that routine pre-BCG urine cultures in asymptomatic patients are unnecessary and may delay appropriate cancer treatment 3.
Risk of BCG Sepsis
The rationale for postponing BCG in active infection is critical to understand: instillation of BCG in the presence of active urinary infection can result in systemic absorption and potentially fatal BCG sepsis 1. When BCG sepsis occurs, it requires immediate ICU transfer, broad-spectrum antibiotics, anti-tuberculosis drugs, and hormone therapy 2. The mortality risk makes this a non-negotiable contraindication.
Common Clinical Scenario: Cystitis Symptoms During BCG Course
If a patient develops cystitis symptoms during an ongoing BCG course 2:
- Mild symptoms: Continue with symptomatic treatment (phenazopyridine, anticholinergics, NSAIDs)
- Symptoms persisting >48 hours or worsening:
- Postpone next BCG instillation
- Perform urine culture
- Start empirical quinolone antibiotics
- Consider dose reduction of BCG for subsequent instillations if symptoms recur
Prophylactic Quinolone Use
Oral quinolones administered after (not before) BCG can reduce toxicity by up to 20% 1. This is Level A evidence supporting routine consideration of post-BCG quinolones for all patients, but they must be given at least 6 hours after BCG instillation to avoid killing the therapeutic bacteria 1.
Recent Evidence on UTI Incidence During BCG
A 2025 retrospective study of 240 patients found that 39.1% developed UTIs during BCG therapy, with E. coli being the most common pathogen (80.7% of susceptible UTIs) 4. Risk factors included diabetes mellitus, chronic kidney disease, and higher number of BCG cycles. This underscores the importance of vigilant monitoring, particularly in patients with these comorbidities.
Bottom Line for Clinical Practice
Active symptomatic UTI = absolute contraindication to BCG instillation. Treat the infection first, then resume BCG when symptoms resolve. However, asymptomatic bacteriuria does not require treatment or delay of BCG therapy. This distinction prevents unnecessary treatment delays that could compromise bladder cancer outcomes while maintaining patient safety from BCG sepsis risk.